Pharmaceutical Opioids For Chronic Non-cancer Pain: Evaluating Health Outcomes And Economic Impact Over Five Years
Funder
National Health and Medical Research Council
Funding Amount
$775,922.00
Summary
Chronic non-cancer pain (CNCP) is a major contributor to disability. Increased opioid prescribing for CNCP has produced concern about dependence and overdose in the absence on data on its long-term effectiveness. Novel statistical methods will test causal relationships over 5 years between treatment, outcomes, and costs on 1,514 CNCP patients prescribed opioids. We will answer critical questions on 5-year outcomes, and whether, and for whom, opioids and other clinical interventions reduce costs.
Cash Transfers And Behaviour Change Communications To Reduce Child Undernutrition In Rural Bangladesh: A Cluster Randomized Controlled Trial To Determine The Most Effective Combination Of Interventions.
Funder
National Health and Medical Research Council
Funding Amount
$3,415,801.00
Summary
Under-nutrition of children remains a major global public health problem. Tackling this problem will require more evidence about what combination of nutrition-specific and nutrition sensitive interventions is most effective in reducing child undernutrition. We plan a large scale trial in rural Bangladesh to compare the effects of communications about nutrition with mobile phones and cash transfers in preventing child malnutrition.
Developing An Australian Valuation For The EQ-5D-5L Quality Of Life Instrument
Funder
National Health and Medical Research Council
Funding Amount
$348,357.00
Summary
In the assessment of gains resulting from a health technology, it is standard to consider both mortality and quality of life effects. This project explores how Australians value different components of quality of life. To do this, we are running an online survey called a discrete choice experiment, and analysing the data using a range of cutting-edge econometric techniques. This will allow policy-makers to better reflect people's preferences when making decisions about new technologies.
Preventing Hospital Readmission In A Regional Australian Hospital Setting
Funder
National Health and Medical Research Council
Funding Amount
$565,695.00
Summary
Hospitals face high levels of emergency presentations and demand for inpatient care particularly for Aboriginal Australian people from remote communities. Readmissions lead to overcrowded emergency departments and poorer patient outcomes. We will evaluate the efficacy of a multidimensional case-based management intervention linking hospital and primary health in a regional Australian hospital with the aim of reducing hospital readmission and improving patient outcomes.
Which Heart Failure Intervention Is Most Cost Effective In Reducing Hospital Care (WHICH? II) Trial: A Multicentre, Randomised Trial Of Standard Versus Intensified Management Of Metropolitan And Regional-dwelling Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$1,891,210.00
Summary
Chronic heart failure (CHF) management programs are now the gold-standard to cost-effectively care for thousands of Australians hospitalised with CHF each year. We’ve shown that home-based management is most cost-effective in reducing hospital stay in CHF. The Which Intervention is most Cost-effective in reducing Hospital care (WHICH? II) Trial, a multicentre, randomised study, will determine if more intensive care (via home visits and remote care contacts) further improves poor outcomes in CHF.
CKD-FIX: A Randomised, Controlled Trial Of Allopurinol In The Slowing Of Kidney Disease Progression
Funder
National Health and Medical Research Council
Funding Amount
$1,917,147.00
Summary
Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.